

Study of association of MTHFR 677 C→T gene polymorphism in coronary artery disease

Shetty Prithviraj Manohar Vijaya¹, Qadri Zareeful Huda¹, Murarka Arpith², Mittal Honey², David Mary^{3*}, Vidhate Deepali Amarsin⁴, Thomas James⁵

{¹BTech Students, ²Assistant Professor, ³Associate Professor, ⁴Associate Professor, Department of Biotechnology}, {⁵Professor and HOD, Department of Cardiovascular and Thoracic Surgery}, D. Y. Patil Deemed to be University School of Biotechnology and Bioinformatics, Belapur, Navi Mumbai, Maharashtra, INDIA.

²MBBS Students, D. Y. Patil School of Medicine, Nerul Navi Mumbai, Maharashtra, INDIA.

Email: mary.david@dypatil.edu

Abstract

Coronary Artery Disease (CAD) continues to be a major cause of mortality, globally for the last few decades. Hyperhomocysteinemia (HCA) resulting from MTHFR 677 C→T polymorphism as a reason for CAD in India has been debatable. The purpose of this study was to analyze the possible association between MTHFR 677C→T polymorphism with CAD by performing a case control study in subjects from Navi Mumbai. Subjects with CAD (n=49) below the age of 65 were compared with a similar number of age and gender matched controls without CAD. According to genotypic analysis, 46 and 48 individuals with CC genotype; 3 and 1 individual with CT genotype were found in cases and controls respectively. No individuals with TT genotype were found in either group. Statistical analysis of biochemical parameters revealed significantly higher levels of plasma homocysteine (Homocysteine) in cases than in controls (p= 0.00), which was statistically significant. However the analysis did not show a significant difference in the Homocysteine levels of CC and CT genotypes within the cases (or in controls). The T allele presents a higher relative risk (OR= 3.0632) in susceptibility to CAD, however, this is not statistically significant (p = 0.3361). Although our study failed to find any association between the existing polymorphisms of MTHFR gene and CAD, it did find an association between HCA and CAD.

Key Words: C677T MTHFR, CAD, homocysteine, hyperhomocysteinemia.

*Address for Correspondence:

Dr. David Mary, Associate Professor, Department of Biotechnology, D. Y. Patil Deemed to be University School of Biotechnology and Bioinformatics, Belapur, Navi Mumbai, Maharashtra, INDIA.

Email: mary.david@dypatil.edu

Received Date: 11/01/2018 Revised Date: 10/02/2018 Accepted Date: 02/03/2018

DOI: <https://doi.org/10.26611/202711>

Access this article online

Quick Response Code:



Website:

www.medpulse.in

Volume 8
Issue 2

INTRODUCTION

Coronary Artery Disease (CAD) is one of the biggest challenges in healthcare the world is facing today. Globally, an estimated 7.4 million people lost their lives due to CAD in the year 2015¹. In recent years, the prevalence and mortality due to CAD is declining in the

developed countries, but sadly that is not the scenario in the developing ones². According to the *Second Indo-US Healthcare Summit*, the prevalence of CAD in India, a developing country, has increased 300%, in the last 30 years, with the rate of increase in CAD accelerating to 6-8% per year³. Reports from the Registrar General of India show that in 2001-2003, CAD accounted for 17% of the total deaths, which further rose to 23% in 2010-2013⁴. CAD is a multifactorial disorder. Obesity, Type 2 diabetes are its co morbidities. Inflammation plays an important role in developing CAD in obese and diabetic patients^{6,7}. Some routine biomolecules also play an important role as cardiac markers⁸ and homocysteine is one of it⁹. In the year 1969, Dr. Kilmer S. McCully, M.D., checked the relationship between the death due to heart attack of an 8 week old infant with a cobalamine metabolism defect and the death due to stroke of an 8 year old patient having homocysteinuria^{10,11}. He

concluded that elevated homocysteine concentrations in the blood lead to atherosclerosis. Homocysteine is an endothelial toxin which can cause inflammation of the endothelial lining of blood vessels, causing atherosclerosis, myocardial infarction, heart failure and stroke¹². Normal levels of homocysteine in the blood range from 4 – 15 $\mu\text{mol/L}$. Hyperhomocysteinemia (HCA), a condition characterized by levels of homocysteine greater than 15 $\mu\text{mol/L}$, results from a diet high in animal protein and low in fruits and vegetables since these vegetables are the source of folic acid and other B vitamins required for metabolizing homocysteine³³. HCA can cause arterial stiffness as it may bring about remodelling of the arterial wall causing arterial damage¹². This condition also predisposes individuals to an increased platelet adhesion to vascular walls and increases thrombotic tendency¹². Apart from diet, another etiological culprit incriminated in causing HCA leading to CAD is the genetic factor. Mutations in several genes may be culpable in the development of HCA and CAD. One such gene is the Methylene tetrahydrofolate reductase (MTHFR) gene, incumbent at chromosome 1p 36.3, having several mutations of which C677T is the most notorious one. C677T is implicated in several disorders viz. Down's syndrome, Acute Lymphoblastic Leukemia, Colorectal cancer, Ischemic stroke and also in atherosclerosis leading to CAD¹². The enzyme MTHFR as the name suggests, reduces 5,10-methylenetetrahydrofolate to the predominant circulatory form of folate, namely 5-methyltetrahydrofolate. The product so formed acts as a single carbon donor for remethylation of homocysteine to methionine¹³ [Figure 1]. Methionine itself serves as a precursor for synthesis of S-adenosyl methionine (SAM), which serves as a methyl donor in most methylation reactions viz. the methylation of DNA, proteins, neurotransmitters and phospholipids¹². A mutation at the 677th position of the gene, replacing a C with a T, leads to substitution of Valine in place of Alanine in the translated enzyme¹⁴. This substitution gives rise to a thermo-labile enzyme with reduced or no activity at all^{15,16}, ultimately leading to HCA and hypomethylation of the before mentioned biomolecules (because of a paucity of SAM) both of which have far reaching consequences. The objective of this study is to examine the association between MTHFR 677C→T gene polymorphism and CAD in the subjects from Navi Mumbai by performing a case control study; and to evaluate the possibility of using MTHFR C/T alleles as markers for screening and identification of patients predisposed to hyper homocysteinemia and at risk for developing Coronary Artery Disease.

MATERIAL AND METHODS

Subject selection: This Case-control study was conducted on 98 patients attending the medical OPD at the Dr. D. Y. Patil Hospital and Research Centre, of which half the subjects, 49, were diagnosed with CAD while the remaining half were healthy subjects tested negative for CAD. The subjects included in the study were of either gender in the ratio of 3:1 (male: female) in both the study groups (Case and Control) with their age as or below 65 years, diagnosed with (Cases) or without (Controls) CAD. A signed informed consent was collected from each subject. Approval for the study was obtained from the ethics committee of the hospital prior to its initiation.

Biochemical Analysis: Fasting blood samples anticoagulated with Ethylene diamine tetracetic acid (EDTA) was collected from subjects after 12 hours of fasting for genotypic studies and separately in a plain container with no-anticoagulant to measure the biochemical parameters. *In vitro* quantitative estimation of the following biochemical parameters: homocysteine, total cholesterol (TC), triglycerides (TG), very low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) were carried out at the D. Y. Patil School of Biochemistry and D. Y. Patil Medical College and Research Centre. LDL to HDL ratio was also determined from the above.

DNA extraction and Characterization: Extraction of DNA from whole blood of the subjects was performed using a commercial DNA extraction kit for whole blood (QIAamp DNA Blood Mini Kit, Qiagen, India). The integrity of the extracted DNA was checked by electrophoresing the nucleic acid using 1% agarose gel.

Genotyping: Genotyping of MTHFR gene was performed using the primers reported from prior study by Matam *et al*²⁵ [Table 1]. *In silico* verification of primers was performed using Primer Blast¹⁷. PCR reactions were performed in a thermal cycler (Bio-Rad, USA) programmed with an initial denaturation at 94 for 4 minutes, followed by 35 cycles of denaturation at 94 for 30 seconds, annealing at 54 for 45 seconds and extension at 72°C for 45 seconds and terminating the process with a final extension at 72 for 12 minutes. Amplification of the 198bp MTHFR C677T SNP containing segment was confirmed by subjecting the PCR product to electrophoresis using 2% agarose gel. The PCR products were digested at 37°C for 2 hours with 2 units of HinfI enzyme in a total reaction volume of 20 μL . The HinfI enzyme for Restriction Enzyme Digestion was validated using the online software NEB cutter. HinfI digested the 677C→T mutated MTHFR to 175bp and 23bp products which was visualized on a 3% agarose gel. The genotypes observed were either CC (with a 198bp band); or CT

(with 198bp, 175bp and 23bp bands); whereas no TT: (with 175bp and 23bp bands) were observed.

Statistical Analysis: Data analysis was performed using the statistical software for windows IBM SPSS STATISTICS (Version 20). T-test was used for comparing the lipid profile and homocysteine levels between cases and controls and also to compare the same between the genotypes in the patient group. The allelic relative risk of developing disease for allele T relative to allele C was determined using the online software MedCalc Online Calculator¹⁸. Cut Offs for lipid profiles as per ATPIII guidelines were considered to determine the association between the risk profile and CAD¹⁹. The certainty that the population follows Hardy-Weinberg equilibrium was authenticated by calculating Chi Square (χ^2) manually.

RESULTS

Table 1 Information on primers and PCR product

Forward primer	TGAAGGAGAAGGTGTCTGCGGGA
Reverse primer	AGGACGGTGCGGTGAGAGTG
Product length	198 bps

Table 2: Comparison of lipid profile and plasma homocysteine levels between cases and controls

Profile	Cases (n=49) (Mean ± SD)	Controls (n=49) (Mean ± SD)	P value
TC (mg/dL)	206.0163 ± 52.54342	178.9653 ± 38.50107	0.005
TG (mg/dL)	144.692 ± 61.6358	128.604 ± 60.7465	0.196
VLDL (mg/dL)	29.504 ± 14.3839	25.522 ± 12.3016	0.144
LDL (mg/dL)	130.482 ± 39.2502	110.271 ± 37.1802	0.010
HDL (mg/dL)	42.651 ± 13.8357	43.167 ± 14.4094	0.857
L/H	3.3541 ± 1.55247	2.7978 ± 1.24746	0.053
HOMOCYST EINE(µmol/L)	13.18 ± 3.751	9.43 ± 2.752	0.000

Table 3: The genotypic and allelic frequencies in cases and controls

Groups	Genotypic Frequency			Allelic Frequency	
	CC	CT	TT	C	T
CAD Patients (Cases)	0.94 (46)	0.06 (03)	0.00 (00)	0.97	0.03
Non CAD patients	0.98	0.02	0.00	0.99	0.01

(Controls)	(48)	(01)	(00)		
Total Population	0.96 (94)	0.04 (04)	0.00 (00)	0.99	0.02

Table 4: Calculation of relative risk (Odds Ratio)

Profile	C	T
Odds Ratio (95% CI)	0.3265 (0.0334, 3.1943)	3.0632 (0.3131, 29.9723)
Z Statistics	0.962	
Significance Level	p = 0.3361	

Table 5: Comparison of lipid profile and plasma homocysteine levels between CC and CT genotypes in cases

Profile	Genotype (Cases)		P value
	CC (n=46) (Mean ± SD)	CT (n=3) (Mean ± SD)	
TC (mg/dL)	207.926 ± 48.67	176.733 ± 107.6664	0.324
TG (mg/dL)	147.122 ± 60.2067	107.433 ± 86.0119	0.285
VLDL (mg/dL)	30.059 ± 14.2670	21.00 ± 16.4353	0.295
LDL (mg/dL)	133.678 ± 37.7965	81.467 ± 31.4999	0.024
HDL (mg/dL)	42.659 ± 13.8326	42.533 ± 17.0016	0.988
L/H	3.4493 ± 1.55404	1.8933 ± 0.30925	0.093
HOMOCYSTEINE(µmol/L)	12.93 ± 3.660	17.00 ± 3.606	0.068

Table 6: Analysis of lipid profile as per ATPIII guidelines for cases and controls

Profile (Cut Off values)	Cases	Controls	Statistical Analysis
TC (mg/dL)			P=0.0008 OR = 4.31
Risky (≥ 200)	31	14	95% Confidence Interval (CI) of OR = 1.84-10.07
Optimal (< 200)	18	35	
TG (mg/dL)			P=0.14 OR = 1.88
Risky (≥ 150)	21	14	95% CI of OR = 0.81-4.34
Optimal (< 150)	28	35	
VLDL (mg/dL)			P=0.0027 OR = 3.63
Risky (≥ 30)	29	14	95% CI of OR = 1.56-8.41
Optimal (< 30)	20	35	
LDL (mg/dL)			P=0.0671 OR = 2.15
Risky (≥ 130)	25	16	95% CI of OR = 0.95-4.87
Optimal (< 130)	24	33	
HDL (mg/dL)			P=0.4076 OR = 0.71
Risky (≤ 40)	17	21	95% CI of OR = 0.31-1.6
Optimal (> 40)	32	28	
Homocysteine (µmol/L)			P=0.0016 OR = 27.87
Risky (≥ 15)	18	1	95% CI of OR = 3.54-219.49
Optimal (< 15)	31	48	




Figure 1: The pathway for the metabolism of Homocysteine(in red) in humans showing the role of the enzyme(in red) in the pathway.




Figure 2: Shows the percentage of people above and below the cut-off values for each profile, with the outer circle showing the cases and the inner showing controls; RED for subjects with risky values and BLUE for subjects with optimal values³¹.




Figure 3: Agarose gel picture with two genotypes of MTHFR C677T polymorphism LD = 100 bp DNA molecular ladder

Cases and controls were age matched and ratio of females to males was approximately 2:3 in both the groups. Table 2 shows the statistical analysis of lipid profile. There was a significant difference ($p < 0.05$) recorded between TC, LDL and homocysteine levels of cases and controls. The mean fasting levels of plasma homocysteine in the cases was found to be 13.1 $\mu\text{mol/L}$ and the geometric mean 12.59 $\mu\text{mol/L}$ with the values ranging from 5 to 21 $\mu\text{mol/L}$. Using 15 $\mu\text{mol/L}$ as cut off for plasma homocysteine levels, we got 18 subjects (36.73%) in the case group and 1 in (2.04%) the control group with >15 $\mu\text{mol/L}$. From the PCR – RFLP analysis, individuals with homozygous CC genotype were determined to be 46 (93.88%) of cases and 48 (97.96%) among controls. Individuals with the heterozygous CT genotype in the cases and controls were determined to be 3 and 1 respectively. None of the subjects in either group had the homozygous TT genotype. The genotypic and allelic frequencies are shown in Table 3. We found the prevalence of CT genotype to be 6.12% among the cases and 2.04% in the controls. The T allele frequency in controls was found to be 1.02% and that of the patient group was 3.06%. On calculating odds ratio, it was seen that T allele presents a higher relative risk (OR=3.0632, 95% CI: (0.3131- 29.9723, but $p > 0.05$) in susceptibility to CAD as shown in Table 4. Chi Square (X^2) was found out to be 0.046, i.e. $X^2 < 3.84$, thus proving that the population is in Hardy-Weinberg equilibrium. Homocysteine levels was not found to be significantly different in subjects with CC and CT genotypes among the cases, despite the mean Homocysteine of CT genotype (17 $\mu\text{mol/L}$) being more than that of CC genotype (12.93 $\mu\text{mol/L}$). Among all the biochemical parameters, only LDL levels showed a significant difference between CC and CT genotype in the case group ($p < 0.05$). [Table 5] Cut-offs as per ATP III guidelines for lipid parameters were taken for calculating relative risk of high risk profile over optimal [Table 6]¹⁹. TC, VLDL and homocysteine levels could be significant independent predictors of CAD.

DISCUSSION

In the present study, the frequency of homozygous wild type (CC) genotype was more frequently detected than the other two genotypes with no TT genotype in either of the groups. The T allele presents a higher relative risk (OR = 3.0632) for susceptibility to CAD but the risk was not statistically significant. This could be related to the small sample size which was studied. Also, our study failed to show a significant association between the CT genotype and HCA. The present study showed significantly higher levels of plasma homocysteine concentrations in the case group as compared to the

control group, highlighting the probability of it being an independent risk factor for CAD. The same was observed with serum cholesterol and LDL levels. Like in Gupta *et al.*, (2012)²⁰, even we introduced the cut offs as per ATP III for lipid parameters. The statistics with the cut offs showed a significant difference between the risky and optimal values of lipid parameters establishing a positive association of TC, VLDL and Homocysteine levels with CAD. MTHFR 677C→T polymorphism has received a lot of attention with a few studies around the world showing positive association^{14,21,22}, with CAD and same is the case with a few Indian studies as well^{23,25,27}. A study on a North Indian population reported a significant association between Homocysteine levels and TT genotype, and also stated that the synergy between HCA and the T allele could be affecting the severity of CAD²⁵. A study on a small sample of the Fars province, Iran reported 83.3% prevalence of polymorphic homozygous TT genotype in their cases, further proving MTHFR C677T polymorphism to be an important risk factor for myocardial infarction²². Another study with the East Indian population also reported a positive association of the MTHFR C677T polymorphism with CAD²³. A study in the population of southern part of India noted the association of T allele with the increased risk of CAD²⁶. A meta-analysis by Chao Xuan *et al.*, (2014)²⁷, which included 35 studies on 9,329 cases and 15,076 controls, demonstrated the positive association of the T allele with myocardial infarction²⁷. However, there were also several studies around the world showing negative associations^{13,28-30}. A study in a North Indian population reported that the T allele was not associated with the risk of CAD²⁸. A recent study in a South Indian population also failed to show any association between the polymorphism and the disease¹³. After additional serum folate adjustments, a study in the population of Taiwan reported the association of MTHFR C677T polymorphism with increased plasma Homocysteine but its association with CAD was negative²⁹. Similar results were reported in a study with subjects from Southern Iran, where the polymorphism was associated with the increased Homocysteine levels, but not with CAD³⁰. Our results were concurrent with the results of Eftychiou *et al.*, (2012)³¹ and Gupta *et al.*, (2012)²⁰, where no association was found between MTHFR 677C→T polymorphism and CAD but a positive association was found between high levels of Homocysteine and CAD. The lack of an association may be due to the multifactorial etiology, in coronary artery disease including factors such as diet, exercise, obesity and folate/ cobalamine levels. Some studies suggested that homocysteine causes the inhibition of the hepatic

synthesis of the main HDL apolipoprotein, ApoA1, thus reducing the concentration of HDL^{32, 33}.

CONCLUSION

In conclusion, the current observation did not support the association between MTHFR 677C→T polymorphism and CAD, however, high levels of homocysteine and CAD did show some links.

REFERENCES

- World Health Organization. (2017). Cardiovascular diseases (CVDs). [online] Available at: <http://www.who.int/mediacentre/factsheets/fs317/en/> [Accessed 25 May 2017].
- Krishnan, M. (2012). Coronary heart disease and risk factors in India – On the brink of an epidemic?. *Indian Heart Journal*, 64(4), pp.364-367.
- Enas, E. et al (2009). Recommendations of the second Indo-U.S. health summit on prevention and control of cardiovascular disease among Asian Indians. *India Heart Journal*, 61(3), pp.265-274.
- Censusindia.gov.in. (2017). Census of India Website: Office of the Registrar General and Census Commissioner, India. [online] Available at: http://www.censusindia.gov.in/2011-common/sample_registration_system.html [Accessed 25 May 2017].
- Gupta, R., Mohan, I. and Narula, J. (2016). Trends in Coronary Heart Disease Epidemiology in India. *Annals of Global Health*, 82(2), pp.307-315.
- Vidhate D A, Thomas J and Gupte A M. Association of IL-6 with Diabetes Mellitus in Indian Population from Navi Mumbai. *International Journal of Recent Trends in Science and Technology* 2013, 8: 2: 100-102.
- Vidhate DA, Thomas J and Gupte A M. IL-6: An important mediator of obesity based inflammation. *International Journal of Advanced and Innovative Research* 2013; 2: 9: 283-286.
- Thomas J, Vidhate D.A, Thomas B P et al, Association of higher circulatory levels of homocysteine with additional risk factors in CAD patients. *MedPulse – International Medical Journal*, 3(1); 14-19 Jan 2016.
- Thomas James, Vidhate Deepali Amarsinh, Thomas Becky et al, “ Risk of coronary artery disease and its association with high serum Ferritin” *International Journal of Recent Trends in Science and Technology*, (December 2016) 21,2: 96-99.
- Mallory T.(1933). Case records of the Massachusetts General Hospital. Case 19471. Marked cerebral symptoms following a limp of three months duration. *The New England Journal of Medicine*, 209:1063-1066.
- McCully, K. S. (1969). Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. *The American Journal of Pathology*, 56(1), 111–128.
- Ganguly, P. and Alam, S. (2015). Role of homocysteine in the development of cardiovascular disease. *Nutrition Journal*, 14(1).
- Devi, N. (2016). Association of MTHFR gene polymorphisms C677T and A1298C with coronary artery disease. *International Journal of Current Research*. 8. 27309-15.
- Frosst, P., Blom, H., Milos, R., Goyette, P., Sheppard, C., Matthews, R., Boers, G., den Heijer, M., Kluijtmans, L., van den Heuvel, L. and Rozen, R. (1995). A candidate genetic risk factor for vascular disease: a common mutation in methylene tetrahydrofolate reductase. *Nature Genetics*, 10(1), pp.111-113.
- Kang, S., Wong, P., Zhou, J., Sora, J., Lessick, M., Ruggie, N. and Grcevich, G. (1988). Thermolabile methylene tetrahydrofolate reductase in patients with coronary artery disease. *Metabolism*, 37(7), pp.611-613.
- Kang, S., Zhou, J., Wong, P., Kowalysyn, J., Strokosch, G. (1988) Intermediate homocysteinemia: a thermo labile variant of methylene tetrahydrofolate reductase. *The American Journal of Human Genetics*, 43:414-421.
- Ncbi.nlm.nih.gov. (2017). Primer designing tool. [online] Available at: <https://www.ncbi.nlm.nih.gov/tools/primer-blast/> [Accessed 25 May 2017].
- Schoonjans, F. (2017). Odds ratio calculator. [online] MedCalc. Available at: https://www.medcalc.org/calc/odds_ratio.php [Accessed 25 May 2017].
- US NCEP issues ATP III guidelines. (2001). *Inpharma Weekly*, and NA;(1289),p.3.
- Gupta, S., Kotwal, J., Kotwal, A., Dhall, A., Garg, S. (2012) Role of homocysteine and MTHFR C677T gene polymorphism as risk factors for coronary artery disease in young Indians. *Indian Journal of Medical Research*, pp 506-512.
- Andreassi, M., Botto, N., Cocci, F., Battaglia, B., Antonioli, E., Masetti, S., Manfredi, S., Colombo, S., Biagini, A., Clerico, A. (2003) Methylene tetrahydrofolate reductase gene C677T polymorphism, homocysteine, vitamin B12, and DNA damage in coronary artery disease. *Human Genetics*, 112 :171–177.
- Nasiri, M., Roostaei, A., Ehsanian, Z. (2014) Association of Methylene tetrahydrofolate Reductase (MTHFR) Gene C677T and A1298C Polymorphisms with Myocardial Infarction from North of Fars Province. *Research in Molecular Medicine*, 2(3), 36-40.
- Dhar, S., Chatterjee, S., Sengupta, B., Chakrabarti, S., Ray, S. and Dutta, A. (2010). Polymorphisms of methylene tetrahydrofolate reductase gene as the genetic predispositions of coronary artery diseases in eastern India. *Journal of Cardiovascular Disease Research*, 1(3), pp.152-157.
- Tripathi, R., Tewari, S., Singh, P. and Agarwal, S. (2010). Association of homocysteine and methylene tetrahydrofolate reductase (MTHFR C677T) gene polymorphism with coronary artery disease (CAD) in the population of North India. *Genetics and Molecular Biology*, 33(2), pp.224-228.
- Alam, M., Husain, S., Narang, R., Chauhan, S., Kabra, M. and Vasisht, S. (2007). Association of polymorphism in the thermolabile 5, 10-methylene tetrahydrofolate reductase gene and hyperhomocysteinemia with coronary artery disease. *Molecular and Cellular Biochemistry*, 310(1-2), pp.111-117.
- Matam, K., Khan, I., Hasan, Q. and Rao, P. (2015). Coronary artery disease and the frequencies of MTHFR and PON1 gene polymorphism studies in a varied

- population of Hyderabad, Telangana region in south India. *Journal of King Saud University - Science*, 27(2), pp.143-150.
27. Xuan, C., Li, H., Zhao, J., Wang, H., Wang, Y., Ning, C., Liu, Z., Zhang, B., He, G. and Lun, L. (2014) Association Between MTHFR Polymorphisms and Congenital Heart Disease: A Meta-analysis based on 9,329 cases and 15,076 controls. *Scientific Reports*, 4(1).
 28. Pandey, U., Kumari, R., Nath, B., Ganesh, S., Banerjee, I., Hasan, O., Midha, T., Pandey, S. (2011) Association of angiotensin-converting enzyme, methylene tetrahydrofolate reductase and paraoxonase gene polymorphism and coronary artery disease in an Indian population. *Cardiology Journal*, 18, pp. 385–394.
 29. Lin, P., et. al. (2008) High plasma homocysteine is associated with the risk of coronary artery disease independent of methylenetetrahydrofolate reductase 677C→T genotypes. *Asia Pacific Journal of Clinical Nutrition*; 17 (2):330-33.
 30. Saffari, B., Senemar, S., Karimi, M., Bahari, M., Jooyan, N. and Yavarian, M. (2013). An MTHFR Variant, Plasma Homocysteine Levels and Late-Onset Coronary Artery Disease in Subjects from Southern Iran. *Pakistan Journal of Biological Sciences*, 16(16), pp.788-795.
 31. Eftychiou, C. et al. (2012) Homocysteine levels and MTHFR polymorphisms in young patients with acute myocardial infarction: a case control study. *Hellenic Journal of Cardiology*, 53, 189–194.
 32. Liao, D., Tan, H., Hui, R., et al. (2006) Hyper homocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance. *Circulation Research*, 99: 598-606.
 33. Mikael, L., Genest, J., Rozen, R. (2006) Elevated homocysteine reduces apolipoprotein A-I expression in hyper homocysteinemic mice and in males with coronary artery disease. *Circulation Research*, 98: 564-571.

Source of Support: None Declared
Conflict of Interest: None Declared